The two companies will work to identify and develop new treatments for cancer and other serious diseases Amgen and Plexium have announced a research collaboration and licensing agreement to identify and develop new protein degrading treatments for complex diseases.
As part of the agreement, Amgen will use its molecular development portfolio in combination with Plexium
